Company news

Genfit SA news in 2026

Genfit SA's news releases, calls and decks from 2026, newest first.

View company

GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

September 29, 2026

GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

September 28, 2026

Genfit: Résultats financiers du premier semestre 2026 et point sur les activités de la Société

September 27, 2026

GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF

September 14, 2026

GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF

September 13, 2026

GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

September 11, 2026

GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

GENFIT annonce sa participation à la H.C. Wainwright 28th Annual Conference

September 9, 2026

GENFIT présente le potentiel commercial à long terme de sa technologie de diagnostic dans la MASH

September 8, 2026

GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026

September 3, 2026

GENFIT organise un événement virtuel avec un leader d’opinion (KOL) consacré au diagnostic de la MASH le 9 septembre 2026

September 2, 2026

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

July 8, 2026

Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial

July 7, 2026

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

July 2, 2026

GENFIT annonce l’accès à la couverture et le futur remboursement par Medicare aux États-Unis de NASHnext®, une technologie visant à identifier les patients atteints de MASH « à risque »

July 1, 2026

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

June 23, 2026

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

June 15, 2026

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

June 8, 2026

GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter

June 2, 2026

GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026

May 25, 2026

GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update

May 21, 2026

GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents

May 11, 2026

GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

April 20, 2026

GENFIT Announces Publication of the 2025 Universal Registration Document

April 7, 2026

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

April 2, 2026

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

April 2, 2026

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

March 9, 2026

GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update

February 26, 2026

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

February 12, 2026

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

January 13, 2026

GENFIT Announces 2026 Financial Calendar

January 7, 2026

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

January 6, 2026

Decks in 2026